Aurobindo Pharma has reported its audited standalone and consolidated financial results for the fourth quarter and fiscal year ended March 31, 2026. The Board of Directors approved the results during its meeting held on May 21, 2026. Following the announcement, the company published the financial results in newspapers, including Business Standard and Nava Telangana, on May 23, 2026. Aurobindo Pharma has also set margin expectations above 21% for FY27, according to CNBC TV18.

Q4 Financial Highlights

For the quarter ended March 31, 2026, the company reported a consolidated revenue of ₹8,853 crore, representing a 5.6% increase year-on-year from ₹8,382 crore in the corresponding quarter of the previous year. Consolidated net profit rose by 2% to ₹921 crore compared to ₹903 crore in Q4 FY25. EBITDA for the quarter stood at ₹1,801 crore, a marginal increase of 0.5% year-on-year, with an EBITDA margin of 20.3%.

The following table highlights the key operational metrics for the quarter:

Annual Performance

For the fiscal year ended March 31, 2026, Aurobindo Pharma reported a consolidated net profit of ₹3,503 crore, a slight increase from ₹3,484 crore in the previous year. Revenue from operations for the year rose to ₹33,653 crore, compared to ₹31,724 crore in FY25, marking a 6.1% growth. The company reported basic and diluted earnings per share of ₹60.34 for the year.

Segment and Operational Updates

Revenue growth was driven by strong performance in Europe, which grew 30.2% year-on-year to ₹2,795 crore, and Growth Markets, which increased 24.7% to ₹980 crore. The US business reported revenue of ₹3,543 crore, a decline of 13% year-on-year, attributed to seasonality and lower transient product sales. The API segment recorded revenue of ₹1,208 crore, up 12.9% year-on-year.

During the quarter, the company received approval for 9 ANDAs and launched 12 products in the US market. Net Capex for the quarter was $82 million, primarily directed towards capability enhancements and new business developments. The company maintained a strong net cash position, with Net Cash (including investments) standing at approximately $317 million as on March 31, 2026.

FY27 Margin Outlook

Looking ahead, Aurobindo Pharma has set margin expectations above 21% for FY27, as reported by CNBC TV18. This guidance comes on the back of the company's FY26 EBITDA margin of 20.3% in Q4, and reflects management's confidence in improving operational efficiency and business mix going forward.

Aurobindo Pharma Limited has announced a change in its secretarial auditor following a board meeting held on May 21, 2026. The company accepted the resignation of its existing auditor, M/s. MRR & Associates, effective from May 22, 2026. The resignation was attributed to health issues concerning the firm's sole proprietor.

Consequently, the board approved the appointment of M/s. RPR & Associates, Company Secretaries in Practice, as the new Secretarial Auditors. The appointment is for a term of five consecutive years, commencing from FY 2026-27 and extending to FY 2030-31. This decision is subject to the approval of shareholders at the ensuing Annual General Meeting.

Details of the Change

The transition involves the cessation of the previous firm and the onboarding of a new entity to ensure compliance with regulatory requirements. The board meeting, which commenced at 4:30 p.m. and concluded at 6:25 p.m., reviewed the necessary disclosures pursuant to Regulation 30 of the SEBI Listing Regulations.

Key Particulars of Appointment

Profile of New Auditor

M/s. RPR & Associates is a peer-reviewed firm of company secretaries in practice. The firm specializes in delivering professional services across Corporate Laws, SEBI Regulations, and FEMA Regulations. Its expertise includes conducting Secretarial Audits, Due Diligence Audits, and Compliance Audits. The proprietor, Mr. Y. Ravi Prasada Reddy, has over 23 years of experience as a practicing Company Secretary.